***Review Article***



International Journal of Pharmacy and Industrial Research

**ISSN Print 2231 – 3648**

**Online 2231 – 3656**

**TRANSDERMAL THERAPEUTIC SYSTEMS - AN OVER VIEW**

# **\***Sowmya C, Suryaprakash Reddy C, Amrutha V, Anilkumar D, Lohitha M

Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, Andhra Pradesh, India - 515721.

## Abstract

The transdermal patch has become a proven technology which offers a variety of significant clinical benefits over other dosage forms. Transdermal drug delivery system has emerged a new era in controlled release of the drug, maintains steady blood level profiles, reducing systemic side effects, avoiding hepatic first pass metabolism and improved efficacy. TDDS is an excellent mode of delivery which has been explored extensively over the last 25 years with therapeutic success and is suited ideally for the diseases which require chronic treatment. The transdermal route of dug delivery has attracted many researchers due to its biomedical applications, but however, excellent impervious nature of skin which acts as a barrier is the greatest challenge that has to be overcome for successful delivery of drug molecules to the systemic circulation. To achieve this, numerous or several approaches are used such as use of prodrugs/lipophilic moiety, permeation enhancers, physical approaches like iontophoresis, electroporation and sonophoresis, stripping of stratum corneum, hydration of stratum corneum, chemical approaches and biological approaches. This article deals with basic components of TDDS, different approaches and methods of preparation of TDDS, and advanced techniques to facilitate the permeation of drug molecules through the skin.

**Key words:** Transdermal drug delivery, Permeation Enhancers, Stratum Corneum, Electroporation, Iontophoresis, Micro Needles.

## Introduction

Transdermal drug delivery systems which are commonly known as transdermal patches are the dosage forms when applied onto the skin delivers the drug through the skin at a controlled rate into the systemic circulation. The first transdermal patch was approved in 1981 to prevent the nausea and vomiting associated with motion sickness; the FDA has approved more than 3 dozen transdermal products1. The clinical benefits, strong market,

interest of industry and regulatory precedence show why transdermal drug delivery has become a successful and viable dosage form.

The main goal of transdermal products design is to maximize the flux through the skin into the systemic circulation and to minimize the retention and metabolism of drug in the skin2. This route offers various biomedical advantages over conventional routes.

### Advantages of TDDS3

**Author for Correspondence:**

Sowmya C,

Raghavendra Institute of Pharmaceutical Education and Research,

Saigram, KR Pally cross, Chiyyedu, Anantapur, Andhra Pradesh, India– 515721. Email: [drsowmyariper@gmail.com](mailto:drsowmyariper@gmail.com)

* Avoids hepatic first pass metabolism.
* Releases over entire period of medication.
* Low dose and short biological half life drugs.
* Decreases GI side effects.
* Increased patient compliance.
* Self medication is possibl.e
* Non invasive method.
* Avoids risks of IV therapy.
* Termination of drug action is possible.
* Advantageous in patients who are nauseated or unconscious.

### Limitations of TDDS4

* Drug should possess certain specific physicochemical properties for penetration through stratum corneum such as dose should be less(<10mg/day), molecular weight(<500daltons)
* Local irritation at the site of administration such as erythema, itching, local oedema –may be caused by drug/adhesive/other excipients
* Variation in absorption efficiency at different sites of skin
* Cannot deliver ionic drugs

### Structure of skin5

Skin is a multilayered organ covers an area of about 2m2 in an average human adult and it receives 1/3rd of all blood circulating through the body.

### Functions of skin

* Acts as a barrier against physical, chemical and microbial attacks
* Acts as a thermostat in maintaining body temperature
* Play a vital role in regulation of blood pressure
* Disposal of biochemical wastes
* Synthesis and metabolism

Skin is majorly differentiated into 3 layers -

### Epidermis

It composed of polygonal epithelial cells with thickness of about 150µm. Differentiation process occurs frequently which is responsible for the production of horny layer i.e., stratum corneum. Fibrous bundles of keratin are present in between epithelial cells which are proteinous in nature constitutes about 75-85% of protein and the remaining with lipids. Stratum corneum is devoid of vasculature. Following the stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum, stratum germinativum are present.

### Dermis

It composed of polygonal cells, muco polysaccharides, collagen fibers present in a lucid of muco polysaccharides, rich bed of capillaries, lymphatic, nerves, epidermal appendages such as hair follicles, sebaceous glands, sweat glands.

### Hypodermis

It is a highly vascular layer.

### Biochemical nature of skin

* + Synthesis of proteins from precursors of amino acids in dermis
  + Reduction of PH (7 to 6) which affects the absorption of drugs due to the conversion of glucose to lactic acid in epidermis
  + Microbial burden on the surface of the skin affects the absorption of drugs

### Mechanism of absorption of drug through skin6

Percutaneous absorption of drugs occurs through skin in 2 ways

**Transepithelial absorption pathway:** Drug will partition into stratum corneum and then diffuses through dermis into the tissues. For lipophilic drugs, diffusion is the rate limiting step. For hydrophilic drugs, partitioning is the rate determining step.

**Transfollicular pathway or shunt pathway:** Drug will diffuse through the shunts, hair follicles, eccrine glands and enters directly into dermis. There is no rate limitation by stratum corneum in this pathway.

### Basic Components of TDDS

1. **Drug7,8**

Selection of drug for TDDS is based on two properties

### Physicochemical properties

* + Dose should be less (<10mg/day)
  + Molecular weight (<500daltons)
  + Melting point (<2000 C)
  + Aqueous solubility (>1mg/ml)
  + Log P value (1-3)

### Biological properties

* + Short biological half life
  + Should be potent
  + Should be non allergic, non irritant
  + Narrow therapeutic window
  + Should not have any binding capacity to skin proteins
  + Extensive first pass metabolism

### Polymer

It is a vital component in TDDS because these are the agents which control the release of the drug from transdermal device.

### Properties8

* + - Should be stable
    - Should be compatible with drug and other components of TDDS
    - Should provide effective and controlled release of drug

Polymer matrix preparation is done by dispersion of drug in solid or liquid state synthetic polymer base.

### Classification of polymers

**Natural polymers:** cellulose derivatives, natural rubber, zein, gelatin, shellac, waxes, starch, chitosan, gums and its derivatives.

**Synthetic polymers:** polyvinyl alcohol, polyvinyl chloride, polyvinyl pyrrolidene10, polyamide, poly ethylene, poly propylene, poly urea, poly acrylate, poly methyl methacrylate.

**Synthetic elastomers:** polybutadiene, polysiloxane, polyisobutylene, neoprene, nitrile, acetonitrile, hydrin rubber, silicon rubber, butyl rubber

Polymers like polyethylene glycol11, eudragits12, ethyl cellulose and hydroxy propyl methyl cellulose13 are used as matrix type transdermal drug delivery.

### Permeation enhancers14

These are the agents which enhances the permeability of stratum corneum by interacting with structural components of stratum corneum i.e, proteins or lipids to attain higher therapeutic levels of drug. They alter the

protein and lipid packaging of stratum corneum and chemically modifies the barrier functions leading to increased permeability.

Permeation of drugs across the skin is explained by the equation,



J

Where, J = flux

D =diffusion coefficient of the drug c= concentration of diffusing species

Permeation can be increased by solvents, surface active agents, others like bile salts, urea

**Solvents:** They increase penetration by disturbing the hydrophilic and lipophilic nature of skin which results in swelling of aqueous layer.

Eg: water, alcohols (ethanol, methanol), dimethyl acetamide, alkyl methyl butoxide, dimethyl sulfoxide, propylene glycol, isopropyl myristate, silicone fluids

**Surface active agents:** These agents binds, penetrates and interact with skin strongly which causes larger alterations in the structure of skin resulting in the change of the nature of skin and thus the permeability increases.

They are classified into 3 classes

1. Anionic: dioctyl sulphosuccinate, sodium lauryl sulphate, dodecyl methyl sulphoxide, sodium dodecyl sulphate, sodium dodeconoate16
2. Cationic: N,N- bis (2- hydroxyl ethyl) oleyl amine
3. Non ionic: pleuronic F127, pleuronic F68, poly oxy ethylene(20) sorbitan mono oleate

Among the above three categories, non ionic surfactants are preferred widely because they are non irritant.

### Others

Bile salts- sodium taurocholate, sodium glycocholate, sodium deoxy cholate, sodium tetra glycocholate

Urea - It is a hydrophilic carrier which enhances the permeation by hydrating the skin. Fatty acids - oleic acid, undecanoic acid

Fatty alcohols - octanol, nonanol

Polyols – poly ethylene glycol, propylene glycol.

N,N- dimethyl toluamide, anti cholinergic drugs, dioctyl methyl-ß- cyclodextrin, eucalyptol, menthol, soya bean casein, cardamom oil, lemon oil, caraway oil, d-limonene, linoleic acid.

### Other excipients Adhesives Examples16:

Poly acrylates - These are most widely used which are polar in nature and allows to absorb moisture readily and maintains adhesion to the wet skin.

Polyiso butylenes - These have low solvent capacity for drugs, which are composed of high and low molecular weight polymers that provide cohesion and tackiness. These are commonly used in membrane controlled systems.

Silicone – These are characterized by low allergenicity. They mostly dissolves drug poorly and regulate tackiness and cohesion through polymer size.

Hot melt pressure sensitive adhesives (HMPSA) - They melt to a viscosity suitable

for coating but when cooled they are in flow less state. They are thermoplastic in nature. Compounded HMPSA are ethylene vinyl acetate copolymers, paraffin waxes, low density poly propylene, styrene- butadiene copolymers, ethylene- ethacrylate. Uncompounded HMPSA are poly esters, poly amides, poly urethanes.

### Backing layer laminates

It is a pressure sensitive layer for supporting the transdermal device17 and prevents loss of drug from the device. It gives perfect geometry to the patch. It should be flexible.

Eg : metallic plastic laminates, plastic baking with adsorbent pad, occlusive base plate with aluminium foil, adhesive foam pad with polyurethane, aluminium foil discs, vinyl, polyesterfilms, polyester-polypropylene films, polypropylene resin, polypropylene resin, polyurethylene, cotrans9722film, ethylene vinyl acetate.

### Release liner18

It is a protective liner which is removed and discharged immediately before the application of the patch to the skin. It is called as primary packaging material.

### Properties

It should be chemically inert as it is in intimate contact with the transdermal device. It is composed of base layer which is non occlusive (paper fabric) or occlusive (polyethylene, poly vinyl chloride) and a release coating layer made up of Teflon or silicon. Other materials used as release liner are polyester foil metalized laminates.

### Plasticizers

These are the agents that provide plasticity to the transdermal patch.

Eg : di butyl phthalate, polyethylene glycol, tri ethyl citrate, propylene glycol.

### Kinetics of drug permeation through skin19

For a systemically active drug moiety to reach from the site of administration to the target tissues it should possess some properties which are capable of,

* Facilitation of sorption of drug by stratum corneum.
* Passage of drug through epidermis.
* Uptake of drug by capillary network to enter into systemic circulation.

The rate of drug permeation across the skin is given by the equation,

= ps(cd-cr)



Where,

dQ/dt = rate of drug permeation ps = permeability coefficient

cd = concentration of drug in donar compartment(stratum corneum)

cr = concentration of drug in receptor compartment(body)

Drug concentration in the donar compartment should always be greater than in the receptor compartment.

Permeability coefficient of skin tissues to the penetrant molecules is given by the equation,

Ps =

Where,

ks = partition coefficient of penetrant

Dss = diffusivity of penetrant at steady state Hs = thickness of stratum corneum

When cd >> cr; the rate of drug permeation becomes,



= pscd

The rate of drug permeation is maintained constant, if cd is made constant. This is achieved when the release of drug from the patch is constant. This condition is observed when Rr>>Ra,

Where, Rr = rate of release Ra = rate of absorption

When cd>>cs, i.e,when the concentration of drug in stratum corneum is much greater than saturation solubility or equilibrium solubility of the drug in stratum corneum, then the maximum rate of permeation (dQ/dt)m is given by the equation,

( )m = pscs



Where, ( )m = maximum rate of permeation



Ps = permeability coefficient of stratum corneum

Cs = saturation solubility of drug in stratum corneum

**Conclusion:** As the maximum rate of permeation depends upon the permeability coefficient of stratum corneum and saturation solubility of drug in stratum corneum, so the rate of permeation is said to be *stratum corneum limited.*


### Different Approaches for Development of TDDS20

Four approaches are there for the development if TDDS

1. Membrane moderated controlled TDDS
2. Adhesive diffusion controlled TDDS
3. Matrix dispersion type TDDS
4. Micro reservoir controlled TDDS

### Membrane moderated controlled TDDS

Drug reservoir is sandwitched in between drug impermeable backing membrane and a rate controlling polymeric membrane. In this the drugs are homogenously dispersed in a solid polymer matrix or suspended in a viscous liquid medium ( eg: silicone fluid). Drug releases through the rate controlling membrane which is micro porous or non porous (eg: ethylene vinyl acetate copolymer). Beneath the rate controlling polymer, a thin layer of drug compatible, pressure sensitive, hypo allergenic adhesive polymer (eg: silicone or poly acrylate adhesive) to achieve an intimate contact of the transdermal patch to the skin. The rate of release of drug from this type of TDDS can be tailored by varying the polymeric composition, permeability coefficient and thickness of rate controlling membrane and adhesive. Fig 1.



### Fig 1: Membrane moderated controlled TDDS

The rate of drug release from this type of systems is given by





Where,

cR = concentration of drug in the reservoir compartment

pm = permeability coefficient of rate controlling membrane

pa = permeability coefficient of adhesive But,





Substitute pm and pa in the above equation,





Where,

Km/r = partition coefficient for the interfacial partitioning of the drug from reservoir to the membrane

Ka/m = partition coefficient for the interfacial partitioning of the drug from membrane to the adhesive


Dm = diffusion coefficient of the rate controlling membrane

Da = diffusion coefficient of the adhesive

hm = thickness of the rate controlling membrane ha= thickness of the adhesive

### Adhesive diffusion controlled TDDS

Drug release is formulated by dispersing the drug in an adhesive polymer and then spreading the medicated polymer adhesive by solvent casting or by melting the adhesive onto an impervious backing layer. The drug reservoir layer is then covered by a non medicated rate controlling adhesive polymer of constant thickness to produce an adhesive diffusion controlled drug delivery system. Fig 2.



### Fig 2: Adhesive diffusion controlled TDDS

The rate of drug release from this type of systems is given by the equation,





Where,

ka/r = partition coefficient for the interfacial partitioning of drug from the reservoir layer to the adhesive layer.

*Advanced model:*

Multi laminate systems: The rate of release of drug from this system is given by






Where, A(ha) = diffusional path length t = thickness at time t

### Matrix dispersion type TDDS

Drug reservoir is formed by dispersing drug solids in a hydrophilic or lipophilic matrix. This medicated polymer is molded as a disc with certain surface area and thickness. This medicated polymer disc is adhered onto an occlusive base plate in a drug impermeable plastic backing fabricated compartment. The adhesive polymer is spread along the circumference to form a strip of adhesive rim around the medicated disc. Fig 3



### Fig 3: Matrix dispersion type TDDS

The rate of drug release from this type of systems is given by the equation,





Where,

A = initial loading dose

Cp = solubility of drug in polymer


Dp = diffusibility coefficient in polymer When CP = CR, then





### Micro reservoir controlled TDDS

It is a combination of matrix and reservoir dispersion systems. Drug reservoir is formed by dispersing the drug in aqueous polymer matrix solution and then transferred into a lipophilic matrix forming polymer in order to form a several thousands of unleachable, microscopic spheres of drug reservoirs. By immediately cross linking the polymer insitu, the thermodynamically unstable dispersion is stabilized. Thus, a transdermal therapeutic system is formed as a disc which is placed at the centre and surrounded by an adhesive rim. Fig 4



### Fig 4: Micro reservoir controlled TDDS

The rate of release of drug from this type of systems is given by the equation,



Where, M = a/b

A = Ratio of drug concentration in elution medium to the drug solubility.

B = Ratio of drug concentration on the outer edge of polymer coat to the drug solubility.


N = Ratio of drug concentration on the inner layer of interfacial barrier to the solubility of drug in matrix.

Dl, Dp, Dd = Diffusion coefficient of liquid layer, polymer coat membrane, hydrodynamic diffusion layer surrounding the polymer coat. Hl, hp, hd = thickness of liquid layer, polymer coat membrane, hydrodynamic diffusion layer surrounding the polymer coat.

kl, kp, km= Partition coefficient of liquid layer, polymer coat membrane, hydrodynamic diffusion layer surrounding the polymer coat. Sl, sp = solubility in liquid layer, polymer coat membrane.

### Production of Transdermal Therapeutic Systems21


1. **Membrane moderated controlled TDDS**




### Adhesive diffusion controlled TDDS

* 1. Preparation of individual matrix solutions.
  2. Coating the individual matrix layers.
  3. Building the multilayer laminate.
  4. Separation of units in multilayer laminate.
  5. Packaging.

### Matrix dispersion type TDDS



1. **Micro reservoir controlled TDDS**



### Advanced Techniques

To increase the transdermal penetration of drugs, the barrier properties of the skin minimal therapeutic level.

### Iontophoresis22

It is a process of sending the ionic or charged molecules through the skin tissues by using direct current or alternate current by putting in electrolyte solution.

Repulsion occurs by placing same charge of electrode on the same charge of drug molecules which acts as a driving force for the passage of drug molecules. The electrical density used should be less than the pain threshold of the patient which is about 5 milliamperes/ cm2 of the area. A porous moist pad is present in between the skin and electrode plate.

Eg : water soluble drugs, local anaesthetics, corticosteroids

Various iontophoretic techniques are used for sending local anaesthetics and corticosteroids are PHORESOR II, EMPIDUPEL, LIFE

TECH IONTOPHOR. These are manufactured by Alza corporation (USA), Fournier (France), Histamistec(Japan)

### Factors to be considered

* Electrical density
* Drug related factors – size, charge, dose, lipophilicity, pH, ionic strength
* Biological factors – humidity of skin, erosion of skin which differs with different people

### Applications

* Delivery of Oligonucleotide in cancer treatment
* Delivery of peptides having shorter biological half life
* Delivery of Fentanyl which has extensive pre systemic metabolism

### Electroporation23

Electroporation is the process of applying voltage pulses which causes dissociation of stratum corneum results in the formation of pores through which small molecules and other

oligonucleotides can pass through the pores in significant amounts.

Eg : Delivery of oligonucleotides, DNA, peptides, other macromolecules

### Factors to be considered:

* Selection of the pulse voltage i.e, 100 – 300 volts
* Number of pulses applied
* Duration of the pulse
* Gap between the pulses

This method is always used in combination with other therapies *electrochemotherapy* which involves creation of pores by electroporation and then sending the chemotherapeutic drugs to the tumor cells through the pores.

### Sonophoresis24

Sonophoresis is the process of applying high frequency ultrasonic energy helpful in the passage of high molecular weight molecules through the skin.

Ultra sonic energy is of 3 types

1. **Low frequency sonic energy:** It causes acoustic streaming of stratum corneum and during propagation of sonic energy, some oscillations will develop which will enhance the transport of drugs.
2. **Therapeutic frequency sonic energy:** It cause some cavitational effects i.e., the air sacs / air bubbles present in viable tissue collapses during application of sonic energy resulting in the alteration of arrangement in the properties of tissues which helps in the passage of drugs through skin.
3. **High frequency sonic energy:** It causes excessive cavitational effects which are not advisable.

Sonic energy shows synergistic effect along with electroporation and permeation enhancers.

**Limitation**: It increases the temperature of skin which is not advisable

### Applications

* + Delivery of high molecular weight compounds like proteins
  + Transdermal topical application of ointments eg hydrocortisone

### Microneedles25

Microneedles are the devices which are prepared with silicon by the process of microfabrication. They are very small in size with diameter of about <1mm, i.e., 1/100th of human hair. The tip of microneedle is 3- dimensional, very sharp and and narrow shaped consists of a small tiny pump through which the drug enters into the skin in desired quantities.

### Properties

* + Should have sufficient length, such that they can deliver drugs to the target site
  + Should not cause pain when they penetrate the skin
  + Should have excellent physical hardness, such that they can penetrate the stratum corneum having thickness of 10-20µm.

### Potential

* + To supply microlitre volumes of insulin
  + High accuracy, good reproducibility and moderate fabrication cost
  + Highly targeted drug administration to individual cells
  + Very accurate dosing, complex release patterns, local delivery and biological drug stability enhancement by storing in
    - a micro volume that can be precisely controlled
    - They are used to remove fluids from the body for analysis as blood glucose measurements
    - Administration of antidotes in bioterrorism incidents

### Applications

* + - Cellular delivery – DNA vaccine delivery, Desmopressin delivery
    - Local tissue delivery
    - Systemic delivery

### Microblades26

Microblades consists of a cutter having a plurality of microprotrusions having a height chosen with respect to the layer of skin that is to be disrupted and a ‘stop’ for preventing the apparatus from penetrating the skin beyond a predetermined distance. As advancement to the basic technique, a microblade device along with negative pressure was patented for percutaneous sampling of an agent. The use of electrotransport, osmosis or pressure along with protrusions for withdrawing body fluids via a hydrogel medium increased the permeation of decapeptide over the transport period as compared to an ordinary electrotransport device.

### Studies carried out on Transdermal drug delivery system

|  |  |  |
| --- | --- | --- |
| **Drug** | **Purpose** | **Reference** |
| Aceclofenac | NSAID | Rakesh P.Patel etal27 |
| Amlodipine Besilate | Antihypertensive | Hemangi J.Patel etal28 |
| Budesonide | Non halogenated corticosteroid | Rupesh V.Chikale etal29 |
| Carvedilol | Antihypertensive | Mandal Sonjoy etal30 |
| Ketoprofen | NSAID | Shasikant D.Barhate etal31 |
| Fulvestrant | Estrogen receptor antagonist | Vinod K.R etal32 |
| Indapamide | Antihypertensive, diuretic | G S Sanap etal33 |
| Isoxsuprine | Uterine relaxant | K.Subramanian etal 34 |
| Lovastatin | Antilipedemic | Shinde Anil Kumar etal35 |
| Glibenclamide | Antidiabetic | J.R.Patel etal36 |
| Metoprolol Tartrate | Cardioselective β-blocker | Meenakshi Bharkatiya etal37 |
| Sinomenine | Antirheumatic | Yuje Ye etal38 |
| Repaglinide | Antidiabetic | Shailesh.T.Prajapati etal39 |
| Ampicillin sodium | Antibiotic | Janardhanan Bagyalakshmi etal40 |
| Diclofenac sodium | NSAID | Gattani S.G etal41 |
| Indomethacin | NSAID | Liang Fang etal42 |
| Nifedipine | Antianginal | Mohammed Gulzar Ahmed etal43 |
| Nitrendipine | Calcium channel blocker | Y. Madhusudan Rao etal44 |
| Propronolol | β-blocker | Nirav S Sheth etal45 |
| Rotigotine | Antiparkinsonian | Sanford etal46 |
| Tolterodine | Antimuscarinic | Vinay Pandit etal47 |
| Valsartan | Antihypertensive | Gulam Irfani etal 48 |

1. **Needleless syringe26**

Needleless syringe consists of an elongate, tubular duct having a lumen for delivering the particles towards the target tissue. It has a membrane which is ruptured by gas pressure to generate a supersonic gas flow in which therapeutic agent is injected.

### Increase in local temperature26

Increase in local temperature increases blood flow which inturn increases the rate of permeation / transport of active substance into the skin. This method is non-invasive and is advantageous of not using a chemical. Koch etal(2004) used an effective component Opraflux to increase the local skin temperature and observed an increase in transdermal absorption rate of morphine base from 5.7 to 26.4%

Eg: insulin, nicotine, dexamethasone, nitroglycerine, sufenfanil.

### Mechanical vibrations26

Mechanical vibrations can be used for increasing drug absorption through skin. Bernabei (2004) used electric pulses to increase the absorption of substances in conjunction with the mechanical vibrations. Inorder to increase the absorption effect, the frequency and phase of electrical and mechanical vibrations were synchronized.

## Conclusion

The Transdermal route of drug delivery system has attracted many researchers due to its biomedical applications, but however, excellent impervious nature of the skin which acts as a barrier is the greatest challenge that has to be overcome for successful delivery of drug molecules to systemic circulation. This article delivers valuable information regarding

the transdermal drug delivery system and its evaluation details as an excellent reference for the research scientists who are involved in TDDS. Due to the excessive benefits of TDDS, many new research scientists are enthusiastic in the development of newer drugs in our future days. With the wide range of polymers that are being used in the transdermal drug delivery systems, there are still issues faced in terms of skin side effects like rshes, inflammation, burn; crystallization of the drug in the rate controlling membrane altering the of permeation of drug in the skin. All these disadvantages suggests the more research and intensity of materials being employed is required before they are put out for commercial use.

## References

1. Jain NK, Umamaheswari RB. Controlled and novel drug delivery systems, chapter-

13 in Pharmaceutical product development, CBS Publishers and distributors, 2008, pp:441

1. Siva kumar T, Shivaraj A, Panner Selvam R, Tamiz Mani T. Design and Evaluation of transdermal drug delivery of Ketotifen Fumerate. *Int J Pharm Biomed Res*. 1(2), 2010, 42-47.
2. Jain NK. Introduction to novel drug delivery systems. Vallabh Prakashan, Delhi, 2010.
3. Mishra AN. Controlled and novel drug delivery. Edn 1, CBS Publishers and distributors, New Delhi, 1997, pp.100- 101.
4. Yiew W. Chein. Controlled drug delivery, fundamentals and applications. Edn 2, Marcel Dekker, pp.525-526.
5. Jain NK. Introduction to novel drug delivery systems. CBS publications, New Delhi, 2010.
6. Dipen M. Patel, Kavitha K. Formulation and evaluation aspects of transdermal drug delivery system, *Int J of Pharm Sci Rev and Res*. Vol-6, Issue-2, 2011, 83-90.
7. Gupta Indra Kumar, Chokshi Maulesh M. Transdermal drug delivery system: An overview, *Asian J of Pharm Sci and Clinl Res*. Vol-1, Issue-1, 2011, 25-43.
8. Keith AD. Polymer matrix considerations for transdermal drug delivery. *Ind Pharm.*9, 1983, 605.
9. Ubaidulla U, Reddy MV, Ruckmani K, Ahmad FJ, Khar RK. Transdermal therapeutic system of carvedilol: Effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. *AAPS. Pharm. Sci. Tech*. 8 (1), 2007.
10. Bromberg L. Cross linked Polyethylene glycol network as reservoirs for protein delivery. *J Appl Poly Sci.* 59, 1996, 459- 466.
11. Verma PRP, Iyer SS. Transdermal delivery of propronolol using mixed grades of eudragit : Design and *in vitro* and *in vivo* evaluation. *Drug Dev Ind Pharm*. 26, 2000, 471-476.
12. Gannu R, Vamshi VY, Kishan V, Rao MY. Development of Nitrendipine transdermal patches: *In vitro* and *ex vivo* characterization. *Cur Drug Deliv*. 4, 2007, 69-76.
13. Mishra AN. Transdermal Drug Delivery, chapter-5 in Controlled and Novel Drug Delivery by N.K. Jain,2009, p:108
14. Hiren J. Patel, Darshan G. Trivedi. Penetration enhancers for transdermal

drug delivery systems: A Review. *IJPI’S J of Pharm and Cosm.* 68-80.

1. Dipen M. Patel, K Kavitha. Formulation and evaluation aspects of transdermal drug delivery systems; *Int J of Pharm Sci and Res*. 6, 2, 2011, 016.
2. Divyesh Patel, Nirav Patel, Meghal Parmar, Navpreet Kaur. Transdermal drug delivery system: Review, *Int J of Biopharm and Toxicol Res*. 1, 1, 2011, 61- 80.
3. Rakesh P Patel, Ashok H. Baria. Formulation and evaluation considerations of transdermal drug delivery system. *Ind J of Pharma Res*, 3, 1, 2011, 1-9.
4. Mishra AN. Transdermal Drug Delivery, chapter-5 in Controlled and Novel Drug Delivery by Jain NK,2009, p:105-106
5. Yiew W. Chein. Transdermal therapeutic systems, chapter-12 in Controlled drug delivery, fundamentals and applications by Joseph.R. Robinson, Vincent H L.Lee, second edition, Marcel Dekker, p:532-538
6. Mishra AN. Transdermal Drug Delivery, chapter-5 in Controlled and Novel Drug Delivery by N.K. Jain,2009, p:115-118
7. Ajay K Banga. Electrically assisted Transdermal Drug Delivery of Drugs, chapter-27 in Handbook of Pharmaceutical Controlled Release Technology by Donald L wise, 2005, p:567
8. Tani Chen, Robert Langer, James C Weaver. Transdermal Drug Delivery by Skin Electroporation, chapter-29 in Handbook of Pharmaceutical Controlled Release Technology by Donald L wise, 2005, p:597
9. Samir Mitra Gotri, Robert Langer, Joseph Kost. Enhancement of Transdermal

Transport using Ultra Sound in Combination with other enhancers, chapter-30 in Handbook of Pharmaceutical Controlled Release Technology by Donald L wise, 2005, p:607

1. Nahid Tabassum, Aasim Safi, Tahir Khuroo. Microneedle Technology: A New Drug Delivery Systems, *Int J of Res in Pharm and Biomed Sci*. 2, 2011,59-62.
2. Ashok K Tiwary, Bhartisapra, Subheet Jain. Transdermal Drug Delivery: Formulations and Technologies; Recent Patents on Drug Delivery and Formulations,2007, Vol-1, No-1, p:23-36
3. Rakesh P. Patel, Grishma Patel, Ashok Baria. Formulation and evaluation of transdermal patch of Aceclofenac. *Int J of Drug del*, 1, 1, 2009,41-51.
4. Hemangi J. patel, Jitendra S. patel, B.G. Desai, Keyur D. Patel. Design and evaluation of Amlodipine besilate transdermal patches containing film former; IJPRD/2009/PUB/ARTI/Vol- 7/SEP/001
5. Rupesh V.Chikale, Yogesh M. Amgaokar, Updesh B.Lade, Dinesh M. Biyani etal. Design and formulation of transdermal drug delivery system of Budesonide. *Dig J of Nanomat and Biostr*. 6, 2, 2011, 475- 497.
6. Mandal sonjoy, Thimmasetty J, Ratan GN, Kilarimath B H. Formulation and evaluation of Carvedilol transdermal patches. *Int Res J of Pharm*. 2, 1, 2001, 237-248.
7. Shasikant D.Barhate, Kedar R.Bavaskar, Yakshendra S.Saoji, Mrugendra Potdar etal. Development of transdermal drug delivery system of Ketoprofen;

IJPRD/2009/PUB/ARTI/Vol-1/Issue- 10/DEC/009

1. Vinod KR, Shravani P, David Banji, Teja BB. Designing and characterization of reservoir type transdermal formulation of Fulvestrant. *Int J of Pharml Sci Rev and Res*, 5, 3, 2010, 59-63.
2. Sanap GS, Dama GY, Hande AS, Karpe SP, Nalawade SV etal. Preparation of transdermal monolithic systems of Indapamide by solvent casting method and the use of vegetable oils as permeation enhancer. *Int J of Green Pharm*. 2, 2, 2008, 129-133.
3. Subamanian K, SathyaPriya LS, JayaPrakash S, Abhirami A. An approach to the formulation and evaluation of transdermal DDS of Isoxsuprine HCl. *Int J Pharm Sci Tech*, 1 (1), 2008, 22-28.
4. Shinde Anil Kumar J, Paithane Manoj B, More Harinath N. Development and invitro evaluation of transdermal patches of Lovastatin as a anti lipedemic drug. *Int Res J of Pharm*. 1, 2010, 113-121.
5. Patel JR, Gupta JRD, Priyanka Tripathi, Prashant Dubey. Formulation and evaluation of matrix type transdermal patches of Glibenclamide. *Int J of Pharm Sci and Drug Res.*1, 1, 2009, 46-50.
6. Meenakshi Bharkatiya, Rajesh Kumar Nema, Mahip Bhatnagar. Development and characterization of transdermal patches of Metoprolol tartrate. *Asian J of Pharm and Clin Res*. 3 (2), 2010,130-134.
7. Yujie Ye, Jianping Wang, Jinlan Ruan, Changgong Zhang. Development and evaluation of the Sinomenine transdermal patch. *Pak J Pharm Sci.* 21, 4, 2008, 407- 410.
8. Shailesh T. Prajapati, Charmi G.Patel, Chhagen N. Patel. Formulation and evaluation of tansdermal patch of Repaglinide. *ISRN Pharmaceutics*. 1, 1, 2011.
9. Janardhan Bagyalakshmi, Ramachandra Purapu Vamsikrishna, Thengungal Kochupappy Ravi. Formulation, Development and *in vitro* and *in vivo* evaluation of membrane-moderated transdermal systems of Ampicillin sodium in ethanol:pH 4-7 buffer solvent system; *AAPS Pharm Sci Tech*. 8 (1), 2007, 7.
10. Gattani SG, Jadhav RT, Kasture PV, Surana SJ. Formulation and evaluation of transdermal films of Diclofenac sodium. *Int J of Pharm Tech Res*. 1, 4, 2009, 1507- 1511.
11. Liang Fang, Ting Li, Changshun Ren,Manliwang, Ligang Zhao etal. Optimized preparation and evaluation of Indomethacin transdermal patch. *Asian J of Pharm Sci*. 2, 6, 2007, 1507-1511.
12. Mohammed Gulzar Ahmed, Kiran Kumar G B, Satish Kumar B P. Formulation and evaluation of Nifedipine transdermal patches. *J of Pharm Res*. 3, 8, 2010, 1785- 1787.
13. Madhusudhan Rao Y, Ramesh Gannu, Vamshi Vishnu Y, Kishan V. Development of Nitrendipine transdermal patch: *In vitro* and *Ex vivo* characterization; *Cur Drug Deliv.* 4, 1, 2007, 69-76.
14. Nirav S Sheth, Rajan B Mistry. Formulation and evaluation of transdermal patches and to study permeation enhancement effect of Eugenol. *J of Appl Pharm Sci*. 1, 3, 2011, 96-101.
15. Sanford Mark, Scott, Lesley J. Rotigotine transdermal patch: A review of its use in the treatment of Parkinson’s disease. *CNS drugs*. 25, 8, 2011, 699-719.
16. Vinay Pandit, Aisha Khanum, Shyamala Bhaskaran, Vasiha Banu. Formulation and evaluation of transdermal films for the treatment of overactive bladder. *Int J of Pharm Tech Res.* 1, 3, 2009, 799-804.
17. Gulam Irfani, Raga Sunil raj, Amit Tondare, Noola Shivanand. Design and evaluation of transdermal drug delivery system of Valsartan using glycerine as plasticizer. *Int J of Pharm Res and Dev*. 3, 2, 2011, 185-192.